Trials / No Longer Available
No Longer AvailableNCT01432483
Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
The purpose of this study is to provide continued therapy with Denileukin diftitox (ONTAK) to patients who are currently on therapy and who have no other suitable treatment options, where therapy is requested by their physician.
Detailed description
The Access Program will be provided as long as appropriate according to the judgment of the provider. If Denileukin diftitox (ONTAK) becomes commercially available without restriction, then the access program will be discontinued.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Denileukin diftitox (ONTAK) | Given at a dose of 9 or 18mcg/kg/day by intravenous infusion over 30 to 60 minutes for 5 consecutive days every 21 days for 8 cycles. |
Timeline
- First posted
- 2011-09-13
- Last updated
- 2015-01-26
Source: ClinicalTrials.gov record NCT01432483. Inclusion in this directory is not an endorsement.